Home 
Headlines August, 2006 Oxonica signs nanoparticle agreement
Headlines August, 2006 Oxonica signs nanoparticle agreement
Oxonica signs nanoparticle agreement
Tuesday 29th 2006f August, 2006
Nanotechnology firm Oxonica has signed a licence agreement with medical company BD (Becton, Dickinson and Company) for its Nanoplex technology.
Nanoplex is based on gold nanoparticles that have a unique label on their surface. This is used as a "tag" that can be attached "to a wide range of biological markers from infectious diseases, such as flu, through to cancers".
Scientists are able to identify diseases using a method called Surface Enhanced Raman Scattering (SERS), which involves an extremely sensitive laser-based reader.
The agreement with BD will involve a co-operative research programme that will develop the Nanoplex technology.
"I am delighted that we have entered into this relationship with BD, a leader in the clinical diagnostics field, and we look forward to working together to develop products for use in both hospital laboratory and point-of-care settings," said David Browning, chief executive of Oxonica Healthcare.
Gold nanoparticles have many biomedical applications – other recent research includes Swedish scientists using gold nanospheres as carriers in the body. They are useful because they do not affect certain immune system cells.
Nanoplex is based on gold nanoparticles that have a unique label on their surface. This is used as a "tag" that can be attached "to a wide range of biological markers from infectious diseases, such as flu, through to cancers".
Scientists are able to identify diseases using a method called Surface Enhanced Raman Scattering (SERS), which involves an extremely sensitive laser-based reader.
The agreement with BD will involve a co-operative research programme that will develop the Nanoplex technology.
"I am delighted that we have entered into this relationship with BD, a leader in the clinical diagnostics field, and we look forward to working together to develop products for use in both hospital laboratory and point-of-care settings," said David Browning, chief executive of Oxonica Healthcare.
Gold nanoparticles have many biomedical applications – other recent research includes Swedish scientists using gold nanospheres as carriers in the body. They are useful because they do not affect certain immune system cells.
© Adfero Limited
